TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02735512

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood and urine samples

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood and urine samples

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Samples undergo MDSC clinical assay

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Samples undergo MDSC clinical assay

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Samples undergo MDSC clinical assay
Study: NCT02980341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab Deruxtecan
Description: U3-1402 consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a)
Study: NCT02285114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: F/TAF tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: F/TAF tablets administered orally once daily
Study: NCT02980341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab Deruxtecan
Description: U3-1402 consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab Deruxtecan
Description: U3-1402 consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a)
Study: NCT01996410

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Study: NCT02015416

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDC-G305
Description: NY-ESO-1 recombinant protein together with GLA-SE
Study: NCT01788189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study: NCT03146689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical NSAID
Description: Applied four times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Capsaicin
Description: Applied four times daily
Study: NCT01953601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verubecestat 12 mg (Parts 1 and 2)
Description: Verubecestat 12 mg oral tablet, given once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verubecestat 40 mg (Parts 1 and 2)
Description: Verubecestat 40 mg oral tablet, given once daily. Verubecestat 40 mg given to participants in Arm C continuing to study Part 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Verubecestat 40 mg (Parts 1 and 2)
Description: Verubecestat 40 mg oral tablet, given once daily. Verubecestat 40 mg given to participants in Arm C continuing to study Part 2.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 1)
Description: Placebo matching verubecestat, given once daily as an oral tablet.
Study: NCT03891043

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: A 100 micrograms of Selenium was given to be taken twice a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill of 100 micrograms of starch was given to be taken twice a day.
Study: NCT00239746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 200mg taken orally daily for 6-12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mg matched placebo taken orally daily for 6-12 weeks
Study: NCT00692848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procalcitonin dosage PCT-Q test (Brahms, Germany)
Description: Procalcitonin result available to the attending physician
Study: NCT02250482

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Optivate® (Human Coagulation Factor VIII)
Study: NCT01493284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Implantation
Description: Placement of the SJM Portico aortic valve with a transfemoral delivery system
Study: NCT03453034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3233
Description: QD or BID in different stage of this research
Study: NCT00539162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaires completed at baseline and during each follow up visit.
Study: NCT01872598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.
Study: NCT01159366

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: early timing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: early timing
Study: NCT04169048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group training for mothers with Borderline Personality Disorder
Description: The group programme is designed to teach mothers with BPD parenting skills and to reduce dysfunctional parenting attitudes and strategies. The components are: childrens basics needs, mindfulness, stress and stress reduction, dealing with conflicts, dealing with emotions, dysfunctional attitudes, physical contact, parenting rules, self care.
Study: NCT02329067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walnuts
Description: consumption of 43 g walnuts per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walnuts
Description: consumption of 43 g walnuts per day
Study: NCT03982459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision support tool
Description: Internet-Based, interactive decision support tool
Study: NCT00633633

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Monthly visits with the cardiology team and a booklet about coping with heart failure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Monthly visits with the cardiology team and a booklet about coping with heart failure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Exercise training 3 times a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Counseling
Description: Food log, booklet, and a cookbook to help decrease the salt content in your diet.
Study: NCT03599661

Intervention type: OTHER
Intervention: Interview
Description: Participants will review a computer prototype of Fertilit-e alpha. Using an interview guide, participants will be asked about issues of content, functionality, and ease of use (i.e., comprehensibility and usability). Interviews will be completed within 45-60 minutes.

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: All participants will complete an interviewer administered screener for health literacy and self-report items for technology use, eHealth literacy, and need for cognition.
Study: NCT04273945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macitentan 10 mg
Description: Participants will receive macitentan 10 mg film-coated tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Description: Participants will receive macitentan 10 mg film-coated tablets orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macitentan 37.5 mg
Description: Participants will receive macitentan 37.5 mg film-coated tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 37.5 mg
Description: Participants will receive macitentan 37.5 mg film-coated tablets orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macitentan 75 mg
Description: Participants will receive macitentan 75 mg film-coated tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 75 mg
Description: Participants will receive macitentan 75 mg film-coated tablets orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo film-coated tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo film-coated tablets orally.
Study: NCT04583878

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw (Visit 1)
Description: Labs will be drawn at Visit 1, also referred to as screening (within 60 days of diagnosis) with the standard of care labs drawn.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw (Visits 2 and 3)
Description: Labs will be drawn at Visit 2 (12 weeks post-diagnosis with a range of 10-16 weeks) and Visit 3 (12 months ± 30 days) for research purposes only and will be collected at Children's Medical Center and processed at UT Southwestern Medical Center.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw (Visits 2 and 3)
Description: Labs will be drawn at Visit 2 (12 weeks post-diagnosis with a range of 10-16 weeks) and Visit 3 (12 months ± 30 days) for research purposes only and will be collected at Children's Medical Center and processed at UT Southwestern Medical Center.
Study: NCT03866668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole Dosage (Weight Less Than 20 kg) -- 10 mg QD for 8 weeks Esomeprazole Dosage (Weight 20 kg or Greater) -- 10 mg QD for 4 weeks followed by 20 mg QD for 4 weeks
Study: NCT01659892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 5 mg Chewable Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Singulair
Description: 5 mg Chewable Tablet
Study: NCT03929562

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief advice
Description: One 10-minute brief advice session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: Two 45-minute health coaching sessions will use a non-confrontation motivational interviewing (MI) style. Intervention delivery will include expressing concern about unhealthy drinking, providing feedback linking alcohol use and health (related to surgery and general health), advising the patient regarding abstinence or alcohol use reduction, and working with the patient to set a drinking goal if he/she is ready to change. We will also include a personalized feedback component to address the links between pre-operative alcohol use and postoperative morbidity/mortality.
Study: NCT04077255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-EGFR antibody in combination with weekly paclitaxel
Description: Intravenous GC-1118 in combination with weekly paclitaxel for EGFR-amplified cancer cancers as a second-line therapy
Study: NCT02556151

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive lumbosacral magnetic stimulation (rTLSMS)
Description: Patients randomized to Six sessions of weekly therapy with either 1 HZ or 5 Hz or 15 Hz magnetic stimulations of the lumbar and sacral regions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive lumbosacral magnetic stimulation (rTLSMS)
Description: Patients randomized to Six sessions of weekly therapy with either 1 HZ or 5 Hz or 15 Hz magnetic stimulations of the lumbar and sacral regions.
Study: NCT02329067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walnuts
Description: consumption of 43 g walnuts per day
Study: NCT02556151

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive lumbosacral magnetic stimulation (rTLSMS)
Description: Patients randomized to Six sessions of weekly therapy with either 1 HZ or 5 Hz or 15 Hz magnetic stimulations of the lumbar and sacral regions.
Study: NCT04251871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules
Description: Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.~Traditional Chinese Medicines (TCMs) granules: 20g, p.o, bid, for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)
Description: Conventional medicines: oxygen therapy, antiviral therapy (alfa interferon via aerosol inhalation, and lopinavir/ritonavir, 400mg/100mg, p.o, bid) for 14 days.
Study: NCT01417611

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: i-scan CE, SE, TE mode
Description: I-scan technology is the newly developed image enhanced endoscopy technology, classified as a digital contrast method among endoscopic imaging techniques. I-scan has three modes of image enhancement, i.e. surface enhancement (SE); contrast enhancement (CE); and tone enhancement (TE). The three modes (SE, CE and TE) are arranged in series, therefore, it is possible to apply two or more of these three modes at one time. Switching the levels or modes of enhancements can be done on a real-time basis, without any time lag by pushing a relevant button, thus enabling efficient endoscopic observation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: i-scan CE, SE, TE mode
Description: I-scan technology is the newly developed image enhanced endoscopy technology, classified as a digital contrast method among endoscopic imaging techniques. I-scan has three modes of image enhancement, i.e. surface enhancement (SE); contrast enhancement (CE); and tone enhancement (TE). The three modes (SE, CE and TE) are arranged in series, therefore, it is possible to apply two or more of these three modes at one time. Switching the levels or modes of enhancements can be done on a real-time basis, without any time lag by pushing a relevant button, thus enabling efficient endoscopic observation.
Study: NCT00405639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nesiritide
Description: Subjects randomized to this arm will receive 5 microgram/Kg subcutaneous (SQ) injection of nesiritide on Day 1. If after the first SQ injection the subject's systolic blood pressure is \>90 mmHG and no symptoms of hypotension, then the second dose can be increased to 10 microgram/Kg. Subjects will self-administer the second dose 12 hours after the first dose, then self-administer the third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline will be used for placebo.
Study: NCT01396395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: The subjects will receive Nicorandil 5 mg tablet orally three times daily for a period of 12 weeks along with the standard treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard Treatment
Description: The subjects will receive one of the standard anti-anginal therapies which included but not limited to aspirin, ACEI, lipid lowering statins and beta blockers according to the recommendation of guidelines. If the subject's condition permitted, they should take all these medicines. However, the dose, route, frequency and duration were determined by investigators according to subject's specific condition.
Study: NCT01396395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: The subjects will receive one of the standard anti-anginal therapies which included but not limited to aspirin, ACEI, lipid lowering statins and beta blockers according to the recommendation of guidelines. If the subject's condition permitted, they should take all these medicines. However, the dose, route, frequency and duration were determined by investigators according to subject's specific condition.
Study: NCT00844116

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: spirometry
Description: Conventional and telematic spirometry

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spirometry
Description: Conventional and telematic spirometry
Study: NCT00265330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone oral capsules
Description: Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid .
Study: NCT03207906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VBP-926
Description: Topical VBP-926 solution
Study: NCT00620360

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fructose
Description: acute administration of 4 times 0.3g fructose/kg lean body mass

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: acute administration of 4 times 0.3 g/kg fat-free mass oral fructose
Study: NCT04681911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inetetamab
Description: Inetetamab: 8mg/kg for the first dose, 6mg/kg for the following doses, every 3 weeks for one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib: 400mg, oral, every day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine, 1000 mg/m2, d1-d14, 3-week cycle
Study: NCT03207906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VBP-926
Description: Topical VBP-926 solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VBP-926
Description: Topical VBP-926 solution
Study: NCT02457416

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peanut
Description: Treatment with peanut in increasing doses until a maintenance dose
Study: NCT04681911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine, 1000 mg/m2, D1, D8, 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine, 25-30 mg/m2, D1, D8, 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin, AUC = 6, 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel
Description: Albumin paclitaxel, 100 mg/m2, weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin, 1.4 mg/m2, D1, D8, 3-week cycle
Study: NCT02064504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: Dry white to off white powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: Dry white to off white powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: Dry white to off white powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: Dry white to off white powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: Dry white to off white powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: Dry white to off white powder
Study: NCT03281824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-P7 (HM2-MMAE)
Description: Antibody-Drug Conjugate
Study: NCT01635075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 1-mile treadmill walk

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: passive control
Description: 20 min inactivity
Study: NCT02064504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Description: Dry white powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Description: Dry white powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Description: Dry white powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Description: Dry white powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Description: Dry white powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Description: Dry white powder
Study: NCT01883050

Intervention type: DEVICE
Group type: OTHER
Intervention: Self Monitoring Software Application
Description: Computer Software application to track health progress after interventional surgery
Study: NCT01703988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusinersen
Description: Single IT injection for each dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusinersen
Description: Single IT injection for each dose
Study: NCT01189318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate Extended Release
Description: Day 1 50mg, Day 2 50mg, Day 3 150mg, Day 4\~28 50\~150mg (increments and deduction of 50mg are allowed)
Study: NCT02449304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endometrial ablation (4th gen)
Description: Radiofrequency Bipolar endometrial ablation device that is inserted into the uterine cavity to destroy the endometrial lining